• University Hospitals is the first health system in Northeast Ohio to offer donanemab (Kisunla™), an FDA-approved treatment for Alzheimer's disease.
• Donanemab targets and removes beta-amyloid plaques in the brain, potentially slowing cognitive and functional decline in early-stage Alzheimer's.
• The treatment involves monthly IV infusions, with the duration varying from six to eighteen months based on patient response and monitoring for side effects.
• Comprehensive evaluation, including medical history, cognitive tests, and brain imaging, is required to determine patient eligibility for donanemab therapy.